[Studies on the effects of lead on the growth and differentiation of hippocampal neural cells as well as the expression of Oct-2].
OBJECTIVE
In order to explore the effects of lead on the growth and development of cultured hippocampal neural cells and on the expression of Oct-2, the II subtype POU domain protein.


METHODS
Experiment cell model was established using primary culture of hippocampal neural cells from SD rat embryos. Target cells were exposed to lead acetate in the different concentrations, i.e. 10(-1), 10(0), 10(1), 10(2), 10(3) micromol/L, while the control group was given the same quantity of the culture medium. The immunohistochemistry method was utilized to detect the expressions of Neurofilament (NF) and Glial Fibrillary Acidic Protein (GFAP), the markers for neuron and astrocyte, respectively, and the expression of Oct-2 as well.


RESULTS
The results showed that 10 micromol/L lead acetate treatment caused diminishing of neuronal cell body and the decreases of both axon lengths and inter-cellular connections. In addition, 1 micromol/L lead acetate significantly increased the number of GFAP-positive cells compared with the control group (P < 0.05). By image analysis system, 1 micromol/L lead acetate treatment was found to induce a statistically significant increase of the positive area rate concerning Oct-2 expression in hippocampal neurons and astrocytes, while both positive area rate and integral density of light of Oct-2 expression were found to increase markedly in the groups treated by 10 micromol/L lead acetate (P < 0.01).


CONCLUSIONS
Lead acetate treatment may contribute to the inhibitions of both growth and differentiation of hippocampus neurons, and to the stimulation of glial cell hyperplasia simultaneously. In addition, the CNS impairments caused by lead is partly correlated with the enhancement of Oct-2 expression.
Chen
Jun
J
Department of Occupational and Environmental Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Zhu
Wei-guo
WG
Chen
Qiu-sheng
QS
Lu
Ling
L
Chen
Xue-min
XM
D000818:Animals; D001253:Astrocytes / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004268:DNA-Binding Proteins / Q000096:biosynthesis* / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004622:Embryo, Mammalian; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000096:biosynthesis / Q000235:genetics; D006624:Hippocampus / Q000166:cytology / Q000378:metabolism*; D007854:Lead / Q000633:toxicity*; D016900:Neurofilament Proteins / Q000096:biosynthesis / Q000235:genetics; D009474:Neurons / Q000166:cytology / Q000378:metabolism; D050813:Octamer Transcription Factor-2; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D014157:Transcription Factors / Q000096:biosynthesis* / Q000235:genetics
D004268:DNA-Binding Proteins; D005904:Glial Fibrillary Acidic Protein; D016900:Neurofilament Proteins; D050813:Octamer Transcription Factor-2; C489205:Pou2f2 protein, rat; D014157:Transcription Factors; D007854:Lead